<DOC>
	<DOCNO>NCT01482403</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center , placebo-controlled , parallel-group study evaluate sustain virologic response safety mericitabine ( RO5024048 ) combination boceprevir Pegasys/Copegus patient chronic hepatitis C infection . The anticipated time study treatment 48 week .</brief_summary>
	<brief_title>A Study Mericitabine Combination With Boceprevir Pegasys/Copegus Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Chronic hepatitis C infection least 6 month duration Hepatitis C genotype 1a 1b Patients must discontinue prior hepatitis C treatment least 12 week prior enrollment study Patient show previous null response therapy define &lt; 2 log10 IU/mL decrease viral titer least 12 week treatment PEGIFN/RBV Hepatitis C infection genotype genotype 1a 1b Body mass index &lt; 18 &gt; /=36 Hepatitis A , hepatitis B , HIV infection Herbal remedy &lt; /=1 month prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>